Stay updated on Oncolytics Biotech Press Releases
Sign up to get notified when there's something new on the Oncolytics Biotech Press Releases page.

Latest updates to the Oncolytics Biotech Press Releases page
- CheckyesterdayChange DetectedThe latest press release now highlights a planned ESMO presentation on pelareorep’s potential in colorectal cancer, replacing a release about immune responses in liver cancer. The stock quote’s daily change shifted from a decline of $0.05 (−9.12%) to a gain of $0.002 (0.40%).SummaryDifference2%

- Check8 days agoChange DetectedThe stock quote changed from $0.56, up $0.013 (2.39%), to $0.50, down $0.05 (9.12%). The latest press releases now cover a GOBLET study update and patent protection extending into the late 2040s, replacing earlier colorectal cancer study and preclinical-results announcements.SummaryDifference3%

- Check15 days agoChange DetectedOncolytics Biotech’s displayed share price changed from $0.63 to $0.56. The daily movement shifted from a $0.01 decline (−1.56%) to a $0.013 gain (+2.39%).SummaryDifference0.9%

- Check22 days agoChange DetectedThe investor overview now lists a publication on pelareorep’s immune effects in liver cancer and accelerated enrollment in a colorectal cancer study, replacing earlier FDA-pathway and Fast Track announcements. The displayed stock quote has also updated.SummaryDifference3%

- Check29 days agoChange DetectedThe Investor Overview page now shows updated NASD:ONCY stock data: price $0.68, daily change $0.004, and a 0.59% move. These figures replace the previous values of $0.77, $0, and 0.00%.SummaryDifference0.9%

- Check36 days agoChange DetectedThe Stock Information block on the Investor Overview now displays a price of $0.77 with a change of $0 and 0.00%. The previous figures shown were $0.75, -$0.026, and -3.37%.SummaryDifference0.9%

Stay in the know with updates to Oncolytics Biotech Press Releases
Enter your email address, and we'll notify you when there's something new on the Oncolytics Biotech Press Releases page.